Coronavirus company news summary – Australian researchers study hydroxychloroquine as a preventative treatment – Covis studies asthma drug against Covid-19

Allie Nawrat 20 May 2020 (Last Updated May 20th, 2020 08:59)

20 May 2020

Covis Pharma has launched a Phase III clinical trial to evaluate its asthma drug Alvesco (ciclesonide) for the treatment of non-hospitalised, symptomatic Covid-19 patients aged 12 years and above. The company secured the US Food and Drug Administration (FDA) approval to conduct the trial. Alvesco is also being studied in Covid-19 in Australia, Japan, South Korea, Sweden and the UK, among others.

A team involving researchers from Beijing Advanced Innovation Center for Genomics (ICG) at Peking University (PKU) has identified various antibodies with neutralising activity against Covid-19. Based on findings from animal studies, the researchers claim that their neutralising antibody could offer a potential cure and also short-term prevention for the disease.

Australian researchers, led by the Walter and Eliza Hall Institute of Medical Research, have launched a clinical trial to assess hydroxychloroquine for the prevention of Covid-19 in around 2,250 high risk healthcare workers. Named COVID SHIELD the trial will run for four months.

Aetion has entered into a research collaboration agreement with the US Food and Drug Administration (FDA) to use real-world data to gain better insights regarding the course and treatment of Covid-19. The partners will find and analyse fit-for-purpose data sources to characterise patient populations and their medication use.